He’s sweet as honey — but the Chinese just can’t “bear” Winnie the Pooh. The portly cartoon character has been banned from Chinese social media in light of unflattering memes comparing Pooh to President Xi Jinping. Since 2013, users have plastered photos of Pooh walking next to his tall, slender pal Tigger next to ones...
NYS Entity Status
NYS Filing Date
AUGUST 06, 2013
NYS DOS ID#
NYS Entity Type
FOREIGN LIMITED LIABILITY COMPANY
2013 - MAIN STREET POOH, LLC
Around the Web
- Chinese president can’t take a joke, bans Winnie the Pooh on social media
By Lia Eustachewich - Monday Jul 17, 2017
- School apologizes for suggesting students masturbate to avoid sex assault
By Associated Press - Friday Sep 8, 2017
ROCHESTER, N.Y. — A university that during a student orientation session showed a slide that appeared to suggest masturbation as a deterrent to sexual assault has apologized. The Rochester Institute of Technology’s slide featured the Winnie the Pooh character Roo, using the kangaroo character’s name as an acronym about masturbation. A screenshot of the slide...
- The Top 10 Moments of New York Fashion Week
By THE NEW YORK TIMES - Friday Sep 15, 2017
Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.
- Women of Sex Tech, Unite
By ANNA NORTH - Friday Aug 18, 2017
New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]
- IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
By Ben Fidler - Thursday Aug 3, 2017
Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]